Subject: ACCTG 642: Case 10-1‚ SolvGen Inc. Statement of Relevant Facts Direct Drugs Inc. (Direct) has created a plan for the acquisition of SolvGen Inc. (SolvGen)‚ which is a publicly owned company. Direct has engaged an audit team to review agreement and procedures dealing with two separate material agreements. The first agreement is a research and development agreement and the second is a licensing and distribution agreement. The contract states that SolvGen entered into a five year research
Premium Contract Generally Accepted Accounting Principles
Solve Gen Inc. Background By Direct Drugs Inc.(Direct)’s request‚ an Audit engagement team has perform due diligence procedures‚ with an emphasis on the review of two separate material agreements between SolvGen Inc.(SolvGen) ‚ that Direct is planning to acquire‚ and Careway Inc (Careway). First agreement is a research and development agreement ‚ and second agreement is a license and distribution agreement during the first quarter of fiscal year 2010. • What are the deliverables for the
Premium Bookkeeping Double-entry bookkeeping system Contract
When should the milestone payments received to date by SolvGen be recognized as revenue? A: FASB codification (605-28) milestone method SolvGen Inc. is gonging to use the milestone method to recognize the revenue. The milestone method is a recently issued method of recognizing revenue for research and development arrangements under which consideration to be received by the vendor is contingent upon the achievement of certain milestones(FASB codification (605-28) milestone method). Under
Premium Income statement Income Generally Accepted Accounting Principles
period of obligation. SolvGen Inc. This case discusses the company Direct Drugs Inc. and their plans to acquire SolvGen Inc. SolvGen Inc. has two material agreements with Careway Pharma Inc. One of the case requirements asks what the deliverables for the arrangement described in the case study were. These being the research and development agreement and a license and distribution agreement. The next requirement asked when the milestone payments received to date by SolvGen were to be recognized
Premium Contract Contract law Subsidiary
Addenda Summary-2011 Note: Due to the issuance of certain new accounting literature‚ changes in the status of ongoing projects during the past year‚ or evolution of practice‚ the following updates to the existing cases should be noted. Case 03-5a Part I: Trademark Subsequent to the release of the Exposure Draft issued by the FASB and IASB in June 2010 the Boards received a number of comments and is currently reviewing and analyzing these comments. A revised draft of the Exposure Draft is expected
Premium Balance sheet International Financial Reporting Standards Asset